查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2134991

全球注意力不足/過動症 (ADHD) 治療研發管線分析 - 2026 年（第二季洞察與臨床試驗）

Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Analysis, 2026 (Q2 Insights & Clinical Trials)
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 152 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球注意力不足/過動症 (ADHD) 治療藥物研發管線分析預計在預測期 (2026-2035 年) 內將維持強勁的複合年成長率。

隨著製藥公司、生技公司和學術研究機構加強研發更安全、作用更持久、更個人化的注意力不足/過動症 (ADHD) 療法，全球 ADHD 治療藥物研發管線正在穩步擴展。 ADHD 在兒童、青少年和成人的盛行率不斷上升，加上診斷率的提高和人們對神經發育障礙認知的增強，正在加速對創新藥物研發的投資。分析藥物研發管線是 ADHD 治療領域至關重要的策略工具，可用於評估臨床實驗中的療法、臨床開發進展、監管里程碑、競爭格局、許可機會和商業化潛力。

儘管哌甲酯和安非他命等興奮劑仍是治療注意力不足過動症（ADHD）的標準療法，但仍存在許多未被滿足的需求，推動著相關研究的發展。目前的治療方法可能伴隨副作用、潛在的濫用風險、個別差異、睡眠障礙、食慾抑制以及治療中斷等問題。因此，製藥公司正日益關注下一代興奮劑、新型非興奮劑療法、緩釋製劑、選擇性神經傳導物質調變器以及精準醫療方法，以期在提高療效的同時增強安全性。

開發平臺也反映了藥物遞送技術的不斷創新。為了提高治療依從性並實現全天持續的症狀控制，研究人員正在開發多種藥物，包括晚上服用的緩釋製劑、每日一次的療法、防濫用製劑以及長效給藥系統。同時，研究人員也在評估能夠有效緩解過動症症狀並最大限度降低心血管影響、精神不利事件和成癮風險的治療方法。

人工智慧、基因組研究、數位生物標記和真實世界數據正日益助力過動症治療藥物的研發。這些技術能夠改善標靶識別、患者分層、臨床試驗設計以及治療反應預測。分散式臨床試驗、遠端患者監護和電子臨床結果評估也提高了研究效率，加速了臨床藥物的研發進程。

大眾對成人注意力不足過動症（ADHD）的認知度不斷提高、醫療保健支出持續成長、神經科學研究經費不斷增加以及監管部門的支持，都持續推動著全球ADHD治療藥物研發生態系統的發展。隨著許多在臨床實驗藥物進入臨床前和臨床開發階段，預計ADHD治療藥物的研發管線將在預測期內保持活躍。

市場促進因素

過動症患者數量增加

  • 兒童和成人中注意力不足過動症的盛行率不斷上升，加上診斷準確性的提高，持續推動對創新療法的需求。
  • 早期診斷、意識提升以及精神科護理服務的改善，擴大了可能符合治療條件的患者範圍，同時也刺激了製藥業對新藥研發的投資。

對非興奮劑療法的需求日益成長

  • 雖然基於興奮劑的療法繼續展現出很高的療效，但人們對濫用和誤用、心血管安全以及治療耐受性的擔憂，導致對非興奮劑療法的需求不斷增加。
  • 製藥公司正在對選擇性神經傳導物質調變器和新的作用機制進行研究，旨在提高長期安全性，同時維持臨床療效。

藥物傳輸技術的進步

  • 緩釋製劑、延遲釋放膠囊和創新口服給藥系統正成為我們研發管線中關鍵的創新領域。
  • 這些技術可以提高治療依從性，減少給藥頻率，並透過日常活動實現持續的症狀控制。

加大對神經科學研究的投入

  • 各國政府、生技公司、製藥企業和學術機構持續增加對神經發育障礙研究的投資。
  • 資金籌措的增加推動了新治療標靶的發現、生物標記研究以及有前景的候選藥物的臨床開發。

精準醫學簡介

  • 精準醫療正透過生物標記辨識、藥物基因體學和個人化治療策略，逐步影響過動症治療的發展。
  • 先進的分析技術提高了患者選擇的準確性，並促進了更有效率的臨床開發項目。

市場限制因素

複雜的臨床開發

  • ADHD 的臨床試驗需要廣泛的安全監測、長期的追蹤期以及對認知功能和行為結果的仔細評估。
  • 這些要求導致開發週期延長，整體研發成本增加。

監管挑戰

  • 治療過動症的新療法必須證明其具有長期療效、心血管安全性、無濫用風險和可接受的耐受性，才能獲得監管部門的批准。
  • 全面的監管要求可能會延緩有前景的候選藥物的商業化。

高昂的研發成本

  • 藥物研發、多中心臨床試驗、生產最佳化和監管申報都需要大量的資金投入。
  • 小規模的生物技術公司可能會依靠策略合作夥伴關係和授權協議來推進其在研產品的開發。

目錄

第1章：引言

  • 調查方法
  • 調查範圍
    • 分析：按公司
    • 分析：按發展階段
    • 分析：按干預類型分類
    • 分析：按臨床試驗狀態
    • 分析：按地區
  • 數據來源和檢驗
  • 定義和假設

第2章 疾病概述

  • 疾病分類
  • 病因和風險因素
  • 症狀和臨床觀察
  • 診斷
  • 目前治療狀況
  • 流行病學和疾病負擔
  • 未滿足的臨床需求

第3章執行摘要

  • 臨床階段產品線概覽
  • 按開發階段分類的管道分佈
  • 臨床試驗活動中的主要公司
  • 主要臨床實驗藥物和療法
  • 各地區臨床試驗現狀
  • 管道構建中的關鍵趨勢和發現

第4章：注意力不足過動症（ADHD）發展過程的動態

  • 促進因素
  • 抑制因子
  • 潛在機會

第5章 管道分析/預測

  • 管道分析：按公司分類
    • Otsuka Pharmaceutical
    • Cingulate
    • Supernus Pharmaceuticals
    • Tris Pharma
    • Takeda Pharmaceutical Company
  • 管道分析：依開發階段分類
    • 第一階段
    • 第一階段
    • 第一/二期
    • 第二階段
    • 第二/三期
    • 第三階段
  • 管道分析：依干預類型分類
    • 製藥
    • 生物
    • 基因
  • 產品線分析：依疾病/患者群分類
    • 兒童注意力不足過動症
    • 青少年注意力不足過動症
    • 成人注意力不足過動症
  • 研發管線分析：依臨床試驗狀態分類
    • 我們尚未開始招募參與者。
    • 招募測試對象
    • 目前尚未招募任何參與者。
    • 完成
    • 取消/撤回/暫停
  • 管道分析：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 臨床試驗和病患分析
    • 按註冊患者人數統計的臨床試驗
    • 依研究設計進行的臨床試驗
    • 患者年齡要求
    • 關於患者性別的合格標準
  • 贊助和合作關係分析
    • 主要商業贊助商
    • 主要學術和研究贊助商
    • 主要合作夥伴組織
    • 對贊助商和合作研究機構的分析
  • 近期和未來管道趨勢
    • 近期啟動的臨床試驗
    • 目前正在招募受試者的臨床試驗
    • 近期完成的臨床試驗
    • 後期臨床試驗接近主要完成階段
    • 近期已發表結果的臨床試驗

第6章：公司簡介

  • Otsuka Pharmaceutical
  • Cingulate
  • Supernus Pharmaceuticals
  • Tris Pharma
  • Takeda Pharmaceutical Company

第7章 圖表清單

第8章：圖表清單

簡介目錄
Product Code: KSI-008891

Global Attention Deficit Hyperactivity Disorder (ADHD) Drug Pipeline Analysis is projected to register a strong CAGR during the forecast period (2026-2035).

The global attention deficit hyperactivity disorder (ADHD) drug pipeline is expanding steadily as pharmaceutical companies, biotechnology firms, and academic research organizations intensify efforts to develop safer, longer-acting, and more personalized therapies for ADHD. The growing prevalence of ADHD across children, adolescents, and adults, combined with increasing diagnosis rates and heightened awareness of neurodevelopmental disorders, has accelerated investment in innovative drug discovery. Drug pipeline analysis has become a critical strategic tool for evaluating investigational therapies, clinical development progress, regulatory milestones, competitive positioning, licensing opportunities, and commercialization potential across the ADHD treatment landscape.

Although stimulant medications such as methylphenidate and amphetamine formulations remain the standard treatment for ADHD, several unmet clinical needs continue to drive research. Current therapies may be associated with adverse effects, abuse potential, variable patient response, sleep disturbances, appetite suppression, and treatment discontinuation. Consequently, drug developers are increasingly focusing on next-generation stimulants, novel non-stimulant therapies, extended-release formulations, selective neurotransmitter modulators, and precision medicine approaches that offer improved efficacy with enhanced safety profiles.

The pipeline also reflects increasing innovation in drug delivery technologies. Evening-dosed extended-release formulations, once-daily therapies, abuse-deterrent formulations, and long-acting delivery systems are being developed to improve treatment adherence and provide consistent symptom control throughout the day. In parallel, researchers are evaluating therapies that address ADHD symptoms while minimizing cardiovascular effects, psychiatric adverse events, and dependence risks.

Artificial intelligence, genomic research, digital biomarkers, and real-world evidence are increasingly supporting ADHD drug development. These technologies improve target identification, patient stratification, clinical trial design, and treatment response prediction. Decentralized clinical trials, remote patient monitoring, and electronic clinical outcome assessments are also improving study efficiency and accelerating clinical development.

Growing recognition of adult ADHD, increasing healthcare expenditure, expanding neuroscience research funding, and supportive regulatory initiatives continue to strengthen the global ADHD drug development ecosystem. As numerous investigational therapies progress through preclinical and clinical development, the ADHD drug pipeline is expected to remain highly active throughout the forecast period.

Market Drivers

Expanding ADHD Patient Population

  • The growing prevalence and improved diagnosis of ADHD across pediatric and adult populations continue to increase demand for innovative therapeutic options.
  • Earlier diagnosis, greater public awareness, and improved access to psychiatric services are expanding the addressable patient population while encouraging pharmaceutical investment in new drug development.

Growing Demand for Non-Stimulant Therapies

  • Although stimulant medications remain highly effective, concerns regarding misuse, abuse potential, cardiovascular safety, and treatment tolerability have increased demand for non-stimulant alternatives.
  • Drug developers are investigating selective neurotransmitter modulators and novel mechanisms designed to improve long-term safety while maintaining clinical efficacy.

Advances in Drug Delivery Technologies

  • Extended-release formulations, delayed-release capsules, and innovative oral delivery systems are becoming major areas of pipeline innovation.
  • These technologies improve treatment adherence, reduce dosing frequency, and provide sustained symptom control throughout daily activities.

Increasing Investment in Neuroscience Research

  • Governments, biotechnology companies, pharmaceutical manufacturers, and academic institutions continue to increase investment in neurodevelopmental disorder research.
  • Growing funding supports discovery of new therapeutic targets, biomarker research, and advancement of promising pipeline candidates through clinical development.

Adoption of Precision Medicine

  • Precision medicine is gradually influencing ADHD drug development through biomarker identification, pharmacogenomics, and personalized treatment strategies.
  • Advanced analytical technologies are improving patient selection while supporting more efficient clinical development programs.

Market Restraints

Complex Clinical Development

  • ADHD clinical trials require extensive safety monitoring, long follow-up periods, and careful evaluation of cognitive and behavioral outcomes.
  • These requirements increase development timelines and overall research costs.

Regulatory Challenges

  • Novel ADHD therapies must demonstrate long-term efficacy, cardiovascular safety, abuse liability, and acceptable tolerability before receiving regulatory approval.
  • Comprehensive regulatory requirements may delay commercialization of promising drug candidates.

High Research and Development Costs

  • Drug discovery, multicenter clinical trials, manufacturing optimization, and regulatory submissions require substantial financial investment.
  • Smaller biotechnology companies may depend on strategic partnerships or licensing agreements to advance pipeline assets.

Technology and Segment Insights

By Development Phase

  • Phase II clinical trials account for a significant proportion of the ADHD pipeline as investigational therapies undergo evaluation for efficacy, dose optimization, pharmacokinetics, and safety.
  • Phase III development continues to expand as promising candidates approach regulatory submission, while preclinical and Phase I programs remain active through continuous introduction of novel compounds targeting new neurological pathways.

By Drug Class

  • Small-molecule therapies dominate the current ADHD pipeline due to established manufacturing capabilities and favorable pharmacological characteristics.
  • Extended-release stimulants continue to represent an important development area, while non-stimulant therapies are among the fastest-growing pipeline segments. Additional innovation includes prodrugs, selective neurotransmitter modulators, and novel oral formulations designed to improve therapeutic performance.

By Mechanism of Action

  • Traditional dopaminergic and noradrenergic therapies continue to represent the largest share of clinical development.
  • Pipeline diversification is increasing through investigation of selective receptor modulators and novel central nervous system targets intended to improve efficacy while reducing adverse effects and abuse potential.

By End User

  • Pharmaceutical companies remain the largest participants in ADHD drug development due to sustained investment in research, clinical trials, and commercialization.
  • Biotechnology companies are expanding rapidly by developing first-in-class therapies and innovative delivery technologies.
  • Academic institutions, contract research organizations, and neuroscience research centers continue to contribute significantly through early-stage discovery and collaborative clinical research.

Regional Insights

  • North America dominates the global ADHD drug pipeline due to its advanced pharmaceutical industry, strong biotechnology ecosystem, well-established clinical research infrastructure, and supportive regulatory environment. The United States continues to host the largest number of ADHD clinical development programs and remains a leading center for neuroscience innovation.
  • Europe represents another major market supported by extensive academic collaboration, established pharmaceutical manufacturers, and increasing investment in neurodevelopmental disorder research. Germany, the United Kingdom, France, Italy, and Spain continue to participate actively in multinational ADHD drug development programs.
  • Asia Pacific is expected to register the fastest growth during the forecast period. Expanding pharmaceutical manufacturing capabilities, improving regulatory frameworks, increasing healthcare expenditure, and growing ADHD awareness are encouraging greater clinical research activity across China, Japan, India, South Korea, and Australia.
  • Latin America and the Middle East & Africa are gradually strengthening their clinical research capabilities through healthcare modernization, expanding participation in multinational clinical trials, and increased collaboration with international pharmaceutical companies.

Competitive and Strategic Outlook

  • The global ADHD drug pipeline is characterized by strong competition among multinational pharmaceutical companies, biotechnology firms, academic research institutions, and specialty neuroscience developers. Companies are actively pursuing differentiated therapies that provide improved efficacy, extended duration of action, enhanced safety, and reduced abuse potential.
  • Strategic collaborations, licensing agreements, acquisitions, and co-development partnerships continue to accelerate pipeline advancement while reducing development risk. Artificial intelligence, predictive analytics, pharmacogenomics, and digital clinical technologies are increasingly integrated into discovery and development processes to improve clinical success rates.
  • Future competition is expected to focus on first-in-class mechanisms of action, precision medicine approaches, long-acting formulations, digital-enabled clinical development, and innovative therapies capable of addressing unmet needs across pediatric and adult ADHD populations.

Conclusion

  • The global ADHD drug pipeline is expected to experience sustained expansion as pharmaceutical innovation continues to address significant unmet clinical needs in ADHD treatment. Growing diagnosis rates, increasing investment in neuroscience research, expanding non-stimulant therapeutic development, advances in drug delivery technologies, and adoption of precision medicine are expected to support long-term pipeline growth. Although regulatory complexity, high development costs, and lengthy clinical programs remain important challenges, continued innovation and strategic collaboration are expected to accelerate development of the next generation of ADHD therapies.

Key Benefits of this Report

  • Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
  • Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
  • Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
  • Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
  • Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

  • Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

  • Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
  • Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
  • Competitive positioning, strategies, and market share evaluation, and trade analysis
  • Revenue growth and forecast assessment across segments and regions
  • Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Research Methodology
  • 1.2. Research Scope
    • 1.2.1. Analysis by Company
    • 1.2.2. Analysis by Development Phase
    • 1.2.3. Analysis by Intervention Type
    • 1.2.4. Analysis by Clinical Trial Status
    • 1.2.5. Analysis by Geography
  • 1.3. Data Sources and Validation
  • 1.4. Definitions and Assumptions

2. DISEASE OVERVIEW

  • 2.1. Introduction
  • 2.2. Disease Classification
  • 2.3. Causes and Risk Factors
  • 2.4. Symptoms and Clinical Manifestations
  • 2.5. Diagnosis
  • 2.6. Current Treatment Landscape
  • 2.7. Epidemiology and Disease Burden
  • 2.8. Unmet Clinical Needs

3. EXECUTIVE SUMMARY

  • 3.1. Clinical-Stage Pipeline Overview
  • 3.2. Pipeline Distribution by Development Phase
  • 3.3. Leading Companies by Clinical Trial Activity
  • 3.4. Leading Investigational Drugs and Interventions
  • 3.5. Geographic Clinical Trial Landscape
  • 3.6. Key Pipeline Trends and Findings

4. ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) PIPELINE DYNAMICS

  • 4.1. Drivers
  • 4.2. Restraints
  • 4.3. Pipeline Opportunities

5. PIPELINE ANALYSIS / OUTLOOK

  • 5.1. PIPELINE ANALYSIS BY COMPANY
    • 5.1.1. Otsuka Pharmaceutical
    • 5.1.2. Cingulate
    • 5.1.3. Supernus Pharmaceuticals
    • 5.1.4. Tris Pharma
    • 5.1.5. Takeda Pharmaceutical Company
  • 5.2. PIPELINE ANALYSIS BY DEVELOPMENT PHASE
    • 5.2.1. Early Phase I
    • 5.2.2. Phase I
    • 5.2.3. Phase I/II
    • 5.2.4. Phase II
    • 5.2.5. Phase II/III
    • 5.2.6. Phase III
  • 5.3. PIPELINE ANALYSIS BY INTERVENTION TYPE
    • 5.3.1. Drug
    • 5.3.2. Biological
    • 5.3.3. Genetic
  • 5.4. PIPELINE ANALYSIS BY DISEASE / PATIENT SEGMENT
    • 5.4.1. Pediatric ADHD
    • 5.4.2. Adolescent ADHD
    • 5.4.3. Adult ADHD
  • 5.5. PIPELINE ANALYSIS BY CLINICAL TRIAL STATUS
    • 5.5.1. Not Yet Recruiting
    • 5.5.2. Recruiting
    • 5.5.3. Active, Not Recruiting
    • 5.5.4. Completed
    • 5.5.5. Terminated / Withdrawn / Suspended
  • 5.6. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa
  • 5.7. CLINICAL TRIAL AND PATIENT ANALYSIS
    • 5.7.1. Clinical Trials by Patient Enrollment
    • 5.7.2. Clinical Trials by Study Design
    • 5.7.3. Patient Age Eligibility
    • 5.7.4. Patient Sex Eligibility
  • 5.8. SPONSOR AND COLLABORATION ANALYSIS
    • 5.8.1. Leading Commercial Sponsors
    • 5.8.2. Leading Academic and Research Sponsors
    • 5.8.3. Leading Collaborating Organizations
    • 5.8.4. Sponsor-Collaborator Analysis
  • 5.9. RECENT AND UPCOMING PIPELINE ACTIVITY
    • 5.9.1. Recently Initiated Clinical Trials
    • 5.9.2. Newly Recruiting Clinical Trials
    • 5.9.3. Recently Completed Clinical Trials
    • 5.9.4. Late-Stage Trials Approaching Primary Completion
    • 5.9.5. Trials with Recently Posted Results

6. COMPANY PROFILES

  • 6.1. Otsuka Pharmaceutical
  • 6.2. Cingulate
  • 6.3. Supernus Pharmaceuticals
  • 6.4. Tris Pharma
  • 6.5. Takeda Pharmaceutical Company

7. LIST OF TABLES

8. LIST OF FIGURES